98%
921
2 minutes
20
Background: Subtelomeres are variable regions between telomeres and chromosomal-specific regions. One of the most studied pathologies linked to subtelomeric imbalance is facioscapulohumeral dystrophy (FSHD). In most cases, this disease involves shortening of an array of D4Z4 macrosatellite elements at the 4q35 locus. The disease also segregates with a specific A-type haplotype containing a degenerated polyadenylation signal distal to the last repeat followed by a repetitive array of β-satellite elements. This classification applies to most patients with FSHD. A subset of patients called FSHD2 escapes this definition and carries a mutation in the gene. We also recently described patients carrying a complex rearrangement consisting of a -duplication of the distal 4q35 locus identified by molecular combing.
Methods: Using this high-resolution technology, we further investigated the organisation of the 4q35 region linked to the disease and the 10q26 locus presenting with 98% of homology in controls and patients.
Results: Our analyses reveal a broad variability in size of the different elements composing these loci highlighting the complexity of these subtelomeres and the difficulty for genomic assembly. Out of the 1029 DNA samples analysed in our centre in the last 7 years, we also identified 54 cases clinically diagnosed with FSHD carrying complex genotypes. This includes mosaic patients, patients with deletions of the proximal 4q region and 23 cases with an atypical chromosome 10 pattern, infrequently found in the control population and never reported before.
Conclusion: Overall, this work underlines the complexity of these loci challenging the diagnosis and genetic counselling for this disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/jmedgenet-2018-105949 | DOI Listing |
NEJM AI
September 2025
Department of Bioengineering, Stanford University, Stanford, CA.
Background: Assessing human movement is essential for diagnosing and monitoring movement-related conditions like neuromuscular disorders. Timed function tests (TFTs) are among the most widespread types of assessments due to their speed and simplicity, but they cannot capture disease-specific movement patterns. Conversely, biomechanical analysis can produce sensitive disease-specific biomarkers, but it is traditionally confined to laboratory settings.
View Article and Find Full Text PDFJ Neuromuscul Dis
September 2025
Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
Background: Electrical impedance myography (EIM) has been proposed as an efficient, non-invasive biomarker of muscle composition in facioscapulohumeral muscular dystrophy (FSHD).
Objective: We investigate whether EIM parameters are associated with muscle structure measured by magnetic resonance imaging (MRI), muscle histology, and transcriptomic analysis as well as strength at the individual leg muscle level.
Methods: We performed a multi-center cross-sectional study enrolling 33 patients with FSHD.
bioRxiv
August 2025
Department of Pharmacology, Center for Molecular Medicine, University of Nevada, Reno School of Medicine, 1664 N Virginia St., Reno, NV 89557 USA.
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant myopathy caused by aberrant expression of the retrogene, and it affects skeletal muscles primarily in the face, shoulder, and limbs. In healthy individuals, is expressed in early development and is subsequently silenced in most somatic tissues. The spatiotemporal pattern of DUX4 misexpression beyond the cleavage stage in FSHD is poorly understood because is not well conserved beyond primates.
View Article and Find Full Text PDFNeurol Genet
October 2025
Department of Neurology, University of Rochester, NY.
Background And Objectives: Effective therapies for facioscapulohumeral muscular dystrophy (FSHD) are currently limited. Recombinant human growth hormone (rHGH) combined with testosterone (combination therapy) may have meaningful clinical effects on ambulation, strength, muscle mass, and disease burden. As such, combination therapy has the potential to limit disease progression and functional decline in individuals with muscular dystrophy.
View Article and Find Full Text PDFOrphanet J Rare Dis
September 2025
Université Côte d'Azur, Service Système Nerveux Périphérique & Muscle, Centre Hospitalier Universitaire de Nice, Nice, France.
Background: Facioscapulohumeral muscular dystrophy (FSHD) is characterized by a typical pattern of muscle involvement, yet it encompasses a wide spectrum of phenotypes, including less common features that remain incompletely defined in the literature. While previous studies have highlighted this clinical variability, no consensus has been reached on how to classify uncommon manifestations, nor have specific predictors been identified. This study aims to describe these uncommon features and explore potential predictors, utilizing data from the French FSHD registry.
View Article and Find Full Text PDF